VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

Authors

  • Lidija Todorović Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia https://orcid.org/0000-0003-0672-0693
  • Boban Stanojević Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia; Department of Haematological Medicine, Division of Cancer Studies, Leukemia and Stem Cell Biology Team, King's College London, London, UK; Virocell Biologics Ltd, 12-18 Theobalds Road, London, UK https://orcid.org/0000-0002-4674-0384

DOI:

https://doi.org/10.17305/bjbms.2022.7850

Keywords:

Papillary thyroid cancer, PTC, VHL, biomarker, risk stratification, tumor suppressor

Abstract

Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, with an increasing incidence worldwide. The treatment of PTC is currently the subject of clinical controversy, making it critically important to identify molecular markers that would help improve the risk stratification of PTC patients and optimize the therapeutic approach. The VHL tumor suppressor gene has been implicated in tumorigenesis of various types of carcinoma and linked with their aggressive biological behavior. The role of VHL in the origin and development of PTC has only recently begun to be revealed. In this narrative review we attempt to summarize the existing knowledge that implicates VHL in PTC pathogenesis and to outline its potential significance as a candidate molecular biomarker for the grouping of PTC patients into high and low risk groups.

Downloads

Download data is not yet available.

Author Biography

Boban Stanojević, Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia; Department of Haematological Medicine, Division of Cancer Studies, Leukemia and Stem Cell Biology Team, King's College London, London, UK; Virocell Biologics Ltd, 12-18 Theobalds Road, London, UK

Laboratory for Radiobiology and Molecular Genetics

VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

Downloads

Published

2022-08-27

How to Cite

1.
Todorović L, Stanojević B. VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma. Bosn J of Basic Med Sci [Internet]. 2022Aug.27 [cited 2022Sep.29];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7850

Issue

Section

Reviews